These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 10517657)

  • 1. Mibefradil, a T-type calcium channel blocker, and abnormal rhythm in subacute myocardial infarction.
    Boutjdir M
    J Cardiovasc Electrophysiol; 1999 Sep; 10(9):1236-9. PubMed ID: 10517657
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of mibefradil, a T-type calcium current antagonist, on electrophysiology of Purkinje fibers that survived in the infarcted canine heart.
    Pinto JM; Sosunov EA; Gainullin RZ; Rosen MR; Boyden PA
    J Cardiovasc Electrophysiol; 1999 Sep; 10(9):1224-35. PubMed ID: 10517656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-type calcium channel blockade in the management of chronic ischemic heart disease.
    Marsh JD; Antman EM
    Cardiovasc Drugs Ther; 2000 Oct; 14(5):459-61. PubMed ID: 11101192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of mibefradil, verapamil, and amlodipine on myocardial function and intracellular Ca(2+) handling in rats with chronic myocardial infarction.
    Min JY; Sandmann S; Meissner A; Unger T; Simon R
    J Pharmacol Exp Ther; 1999 Dec; 291(3):1038-44. PubMed ID: 10565822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contrasting effects of selective T- and L-type calcium channel blockade on glomerular damage in DOCA hypertensive rats.
    Karam H; Clozel JP; Bruneval P; Gonzalez MF; Ménard J
    Hypertension; 1999 Oct; 34(4 Pt 1):673-8. PubMed ID: 10523345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Mibefradil--a T-type calcium channel blocker].
    Roguin A; Edoute Y
    Harefuah; 1999 Jan; 136(2):167-9. PubMed ID: 10914190
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of the calcium channel antagonist mibefradil on haemodynamic parameters and myocardial Ca(2+)-handling in infarct-induced heart failure in rats.
    Sandmann S; Min JY; Meissner A; Unger T
    Cardiovasc Res; 1999 Oct; 44(1):67-80. PubMed ID: 10615391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic interaction between mibefradil and other calcium channel blockers.
    Matthes J; Huber I; Haaf O; Antepohl W; Striessnig J; Herzig S
    Naunyn Schmiedebergs Arch Pharmacol; 2000 Jun; 361(6):578-83. PubMed ID: 10882031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beneficial effects of the T- and L-type calcium channel antagonist, mibefradil, against exercise-induced myocardial stunning in dogs.
    Parent de Curzon O; Ghaleh B; Hittinger L; Giudicelli JF; Berdeaux A
    J Cardiovasc Pharmacol; 2000 Feb; 35(2):240-8. PubMed ID: 10672856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of effects of T and N type calcium channel blockers on the electroencephalogram recordings in Wistar Albino Glaxo/Rij rats, an absence epilepsy model.
    Durmus N; Gültürk S; Kaya T; Demir T; Parlak M; Altun A
    Indian J Pharmacol; 2015; 47(1):34-8. PubMed ID: 25821308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanical and thermal antinociception in rats following systemic administration of mibefradil, a T-type calcium channel blocker.
    Todorovic SM; Meyenburg A; Jevtovic-Todorovic V
    Brain Res; 2002 Oct; 951(2):336-40. PubMed ID: 12270514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-type Ca2+ channel blockade prevents sudden death in mice with heart failure.
    Kinoshita H; Kuwahara K; Takano M; Arai Y; Kuwabara Y; Yasuno S; Nakagawa Y; Nakanishi M; Harada M; Fujiwara M; Murakami M; Ueshima K; Nakao K
    Circulation; 2009 Sep; 120(9):743-52. PubMed ID: 19687356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcium channel blockade limits cardiac remodeling and improves cardiac function in myocardial infarction-induced heart failure in rats.
    Sandmann S; Claas R; Cleutjens JP; Daemen MJ; Unger T
    J Cardiovasc Pharmacol; 2001 Jan; 37(1):64-77. PubMed ID: 11152376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antihypertensive effects of the putative T-type calcium channel antagonist mibefradil are mediated by the L-type calcium channel Cav1.2.
    Moosmang S; Haider N; Brüderl B; Welling A; Hofmann F
    Circ Res; 2006 Jan; 98(1):105-10. PubMed ID: 16306443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of in vitro contractions of human myometrium by mibefradil, a T-type calcium channel blocker: support for a model using excitation-contraction coupling, and autocrine and paracrine signaling mechanisms.
    Young RC; Zhang P
    J Soc Gynecol Investig; 2005 May; 12(4):e7-12. PubMed ID: 15866110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two structurally different T-type Ca 2+ channel inhibitors, mibefradil and pimozide, protect CA1 neurons from delayed death after global ischemia in rats.
    Bancila M; Copin JC; Daali Y; Schatlo B; Gasche Y; Bijlenga P
    Fundam Clin Pharmacol; 2011 Aug; 25(4):469-78. PubMed ID: 21039820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T-Type Calcium Channel Inhibitors Induce Apoptosis in Medulloblastoma Cells Associated with Altered Metabolic Activity.
    Sedeeq M; Maklad A; Dutta T; Feng Z; Wilson R; Gueven N; Azimi I
    Mol Neurobiol; 2022 May; 59(5):2932-2945. PubMed ID: 35243582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-channel pharmacology of mibefradil in human native T-type and recombinant Ca(v)3.2 calcium channels.
    Michels G; Matthes J; Handrock R; Kuchinke U; Groner F; Cribbs LL; Pereverzev A; Schneider T; Perez-Reyes E; Herzig S
    Mol Pharmacol; 2002 Mar; 61(3):682-94. PubMed ID: 11854450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mibefradil inhibition of T-type calcium channels in cerebellar purkinje neurons.
    McDonough SI; Bean BP
    Mol Pharmacol; 1998 Dec; 54(6):1080-7. PubMed ID: 9855637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targetting voltage-gated calcium channels in cardiovascular therapy.
    Angus JA; Wright CE; Xi Q
    Lancet; 2000 Oct; 356(9238):1287-9. PubMed ID: 11073011
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.